Regulations last checked for updates: Nov 22, 2026

Title 21 - Food and Drugs last revised: Nov 12, 2026
§ 868.2378 - Over-the-counter device to assess risk of sleep apnea.

(a) Identification. An over-the-counter device to assess risk of sleep apnea is intended to provide a notification of the risk of sleep apnea in users who have not been previously diagnosed with sleep apnea. This device uses software algorithms to analyze input sensor signals and provide a risk assessment for sleep apnea. It is not intended to provide a standalone diagnosis, replace traditional methods of diagnosis (e.g., polysomnography), assist clinicians in diagnosing sleep disorders, or be used as an apnea monitor.

(b) Classification. Class II (special controls). The special controls for this device are:

(1) Clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. This testing must fulfill the following:

(i) Testing must include a study population representative of the intended use population for the device, including subjects symptomatic and asymptomatic of sleep apnea. Any selection criteria or sample limitations must be fully described and justified.

(ii) The assessment must demonstrate output consistency using the expected range of data sources and data quality encountered in the intended use population and environment.

(iii) The assessment must evaluate device performance across all applicable subgroups (e.g., age, sex, body mass index, skin tone).

(iv) The assessment must compare device performance with a clinical comparator device (e.g., polysomnography) to demonstrate the required accuracy and/or sensitivity and specificity of the output measure(s). Justification for the clinical comparator as ground truth must be provided.

(v) For devices with machine learning-based algorithms, the clinical validation must be completed using a dataset that is separate from the training dataset.

(2) Non-clinical performance data must demonstrate that the device performs as intended under anticipated conditions of use. Performance testing must demonstrate hardware compatibility and the ability of the device software and hardware to provide adequate input signal quality and handle noisy or missing data and poor signal quality.

(3) Performance data must be provided to demonstrate the electromagnetic compatibility and electrical, mechanical, and thermal safety of any device hardware components.

(4) Any device hardware components that are skin-contacting must be demonstrated to be biocompatible.

(5) Software verification, validation, and hazard analysis must be performed. Software documentation must include:

(i) Full characterization of the technical specifications of the software, including the detection algorithm and its inputs and outputs.

(ii) A description of the expected impact of all applicable sensor acquisition hardware characteristics, associated hardware specifications, and processing software; and

(iii) A description of all mitigations for failure of any subsystem components (including signal detection, signal analysis, data display, and storage) on output accuracy.

(6) Human factors and usability testing must demonstrate the following:

(i) The user can correctly use the device based solely on reading the directions for use; and

(ii) The user can correctly interpret the device output and understand when to seek medical care.

(7) Labeling must include:

(i) A description of what the device measures and outputs to the user;

(ii) Hardware platform and operating system requirements;

(iii) The type of sensor data used, including specifications of compatible hardware used for data acquisition;

(iv) Warnings identifying sensor acquisition factors or subject conditions or characteristics that may impact measurement results;

(v) Information for interpretation of the measurements, including a statement that the device is not intended to replace traditional methods of diagnosis (e.g., polysomnography) nor intended to be used as an apnea monitor;

(vi) A summary of the clinical performance testing with the device, including both the device's overall performance as well as performance across all relevant subgroups.

[91 FR 68464, Oct. 30, 2026]
authority: 21 U.S.C. 351,360,360c,360e,360j,360
source: 47 FR 31142, July 16, 1982, unless otherwise noted.
cite as: 21 CFR 868.2378